Italia markets closed

Editas Medicine, Inc. (EDIT)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a portafoglio
17,43+0,01 (+0,06%)
Alla chiusura: 04:00PM EST
17,90 +0,47 (+2,70%)
Dopo ore: 07:52PM EST
Schermo intero
Caricamento grafico interattivo in corso...
  • GlobeNewswire

    Editas Medicine Reports on Recent Progress and Outlook at J.P. Morgan Healthcare Conference

    James C. Mullen James C. Mullen, Chairman, President, and Chief Executive Officer of Editas Medicine Anticipated 2022 milestones include initial clinical data for EDIT-301 in sickle cell disease by year-end, dosing of first TDT patient with EDIT-301, initiation of pediatric high-dose cohort for EDIT-101 in LCA10, and a clinical data update on EDIT-101 in the second half of 2022 Company announces new development candidates EDIT-103 for RHO-adRP and EDIT-202 multiplexed iNK cell therapy for solid

  • GlobeNewswire

    Editas Medicine to Present at the 40th Annual J.P. Morgan Healthcare Conference

    CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will present a company overview and update at the 40th Annual J.P. Morgan Healthcare Conference, held virtually, on Wednesday, January 12, 2022, at 10:30 a.m. ET A live webcast of the presentation will be available on the Investors section of the Editas Medicine website at www.editasmedicine.com. An archived replay will be available on the website fo

  • GlobeNewswire

    Dr. Jessica Hopfield Appointed to Berkeley Lights Board of Directors

    Addition of Experienced Independent Director with Accomplished Business Record Underscores Berkeley Lights Board of Directors’ Commitment to Delivering Value for ShareholdersEMERYVILLE, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, today announced the appointment of Jessica Hopfield, Ph.D. to the Berkeley Lights’ Board of Directors as an independent director, effective December 15, 2021. "Dr. Hopfield is a respected and accomplis